AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Chromeno[4,3,2-de]isoquinolines as Potent Dopamine Receptor Ligands

Summary

A compound developed by Purdue University researchers, dinoxyline(8,9-dihydroxy-1,2,3,11b-tetragydrichromeno[4,3,2-de]isoquinoline), provides a novel class of therapeutic agents for any disorder that can be treated by drugs affecting dopamine receptors. Where dihydrexidine is ten-fold D1:D2 selective and dinapsoline is five-fold D1:D2 selective, dinoxyline has an equally high affinity for both D1 and D2 receptors. This is surprising considering the structure of this new compound in comparison to related work with other dopamine agonists. The unexpected result suggests that dinoxyline may bind to the D2 receptor in another way, which could translate into unanticipated therapeutic benefits.

Technology Benefits

Useful in treating certain cognitive disorders and dementiaPotent anti-hypertensive effects Provides novel strategies to treat schizophrenia and drug addiction

Technology Application

Pharmaceutical Industry

Detailed Technology Description

David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

United States

Application No.

6,916,832

Country/Region

USA

For more information, please click Here